Cargando…

Provision and use of radiotherapy in Europe

Radiation therapy is one of the core components of multidisciplinary cancer care. Although ~ 50% of all European cancer patients have an indication for radiotherapy at least once in the course of their disease, more than one out of four cancer patients in Europe do not receive the radiotherapy they...

Descripción completa

Detalles Bibliográficos
Autores principales: Lievens, Yolande, Borras, Josep M., Grau, Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332207/
https://www.ncbi.nlm.nih.gov/pubmed/32293084
http://dx.doi.org/10.1002/1878-0261.12690
_version_ 1783553480644886528
author Lievens, Yolande
Borras, Josep M.
Grau, Cai
author_facet Lievens, Yolande
Borras, Josep M.
Grau, Cai
author_sort Lievens, Yolande
collection PubMed
description Radiation therapy is one of the core components of multidisciplinary cancer care. Although ~ 50% of all European cancer patients have an indication for radiotherapy at least once in the course of their disease, more than one out of four cancer patients in Europe do not receive the radiotherapy they need. There are multiple reasons for this underutilisation, with limited availability of the necessary resources – in terms of both trained personnel and equipment – being a major underlying cause of suboptimal access to radiotherapy. Moreover, large variations across European countries are observed, not only in available radiotherapy equipment and personnel per inhabitant or per cancer patient requiring radiotherapy, but also in workload. This variation is in part determined by the country's gross national income. Radiation therapy and technology are advancing quickly; hence, recommendations supporting resource planning and investment should reflect this dynamic environment and account for evolving treatment complexity and fractionation schedules. The forecasted increase in cancer incidence, the rapid introduction of innovative cancer treatments and the more active involvement of patients in the healthcare discussion are all factors that should be taken under consideration. In this continuously changing oncology landscape, reliable data on the actual provision and use of radiotherapy, the optimal evidence‐based demand and the future needs are crucial to inform cancer care planning and address and overcome the current inequalities in access to radiotherapy in Europe.
format Online
Article
Text
id pubmed-7332207
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73322072020-07-07 Provision and use of radiotherapy in Europe Lievens, Yolande Borras, Josep M. Grau, Cai Mol Oncol Reviews Radiation therapy is one of the core components of multidisciplinary cancer care. Although ~ 50% of all European cancer patients have an indication for radiotherapy at least once in the course of their disease, more than one out of four cancer patients in Europe do not receive the radiotherapy they need. There are multiple reasons for this underutilisation, with limited availability of the necessary resources – in terms of both trained personnel and equipment – being a major underlying cause of suboptimal access to radiotherapy. Moreover, large variations across European countries are observed, not only in available radiotherapy equipment and personnel per inhabitant or per cancer patient requiring radiotherapy, but also in workload. This variation is in part determined by the country's gross national income. Radiation therapy and technology are advancing quickly; hence, recommendations supporting resource planning and investment should reflect this dynamic environment and account for evolving treatment complexity and fractionation schedules. The forecasted increase in cancer incidence, the rapid introduction of innovative cancer treatments and the more active involvement of patients in the healthcare discussion are all factors that should be taken under consideration. In this continuously changing oncology landscape, reliable data on the actual provision and use of radiotherapy, the optimal evidence‐based demand and the future needs are crucial to inform cancer care planning and address and overcome the current inequalities in access to radiotherapy in Europe. John Wiley and Sons Inc. 2020-05-01 2020-07 /pmc/articles/PMC7332207/ /pubmed/32293084 http://dx.doi.org/10.1002/1878-0261.12690 Text en © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Lievens, Yolande
Borras, Josep M.
Grau, Cai
Provision and use of radiotherapy in Europe
title Provision and use of radiotherapy in Europe
title_full Provision and use of radiotherapy in Europe
title_fullStr Provision and use of radiotherapy in Europe
title_full_unstemmed Provision and use of radiotherapy in Europe
title_short Provision and use of radiotherapy in Europe
title_sort provision and use of radiotherapy in europe
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332207/
https://www.ncbi.nlm.nih.gov/pubmed/32293084
http://dx.doi.org/10.1002/1878-0261.12690
work_keys_str_mv AT lievensyolande provisionanduseofradiotherapyineurope
AT borrasjosepm provisionanduseofradiotherapyineurope
AT graucai provisionanduseofradiotherapyineurope